Skip to Content

Clariant AG

Securities Class Action

  • Date:
  • 9/16/2022
  • Company Name:
  • Clariant AG
  • Stock Symbol:
  • CLZNY
  • Status:
  • Investigating

Case Finder

Locate any case using the tools below.

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Clariant AG (“Clariant” or the “Company”) (Other OTC: CLZNY) on behalf of Clariant stockholders. Our investigation concerns whether Clariant has violated the federal securities laws and/or engaged in other unlawful business practices.

On February 14, 2022, Swiss chemical maker, Clariant AG, disclosed that it will delay issuing Q4 2021 and full year 2021 financial results due an ongoing internal investigation into potential accounting fraud.

Clariant AG is investigating internal whistleblower complaints that the company has known about since September 2021, pertaining to booking issues aimed at boosting results to meet targets.

On this news, shares of Clariant AG ADR shares fell more than 14% in intraday trading on February 14, 2022.

If you purchased or otherwise acquired Clariant shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Alexandra Raymond by email at investigations@bespc.com, telephone at (212) 355-4648, or by filling out the form below.  There is no cost or obligation to you.
 
The individual or institution below (“Plaintiff”) has reviewed and agrees to the Bragar Eagel & Squire, P.C. (“BESPC”) retainer agreement and authorizes BESPC to prosecute an action on Plaintiff’s behalf under the federal securities laws or applicable state laws to recover damages on behalf of investors in Clariant AG. BESPC will prosecute the action on a full contingency basis and will forward all costs and expenses.
 

Case Finder

Locate any case using the tools below.

You may share a link to this page on any of the sites listed below or send link via email: